New pill targets hard-to-treat cancers in early trial
NCT ID NCT05462717
First seen Apr 11, 2026 · Last updated May 16, 2026 · Updated 7 times
Summary
This early-phase study tests an experimental drug called RMC-6291 in adults with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to find a safe dose and see how the body processes the drug. About 222 people with lung, colorectal, or pancreatic cancer that has not responded to standard treatments will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ajou University Hospital
Suwon, Gyeonggi-do, 16499, South Korea
-
American Oncology Partners of Maryland
Bethesda, Maryland, 20817, United States
-
Austin Health, Olivia Newton-John Cancer Research & Wellness Centre
Heidelberg, Victoria, 3084, Australia
-
Azienda Ospedaliero-Universitaria San Luigi Gonzaga
Orbassano, 10043, Italy
-
CHU Bordeaux Hospital Saint-Andre
Bordeaux, 33000, France
-
CHU Nantes
Nantes, 44093, France
-
Centre Jean Perrin
Clermont-Ferrand, 63011, France
-
Centre Léon Bérard
Lyon, 69008, France
-
Centre Oscar Lambret
Lille, 59000, France
-
Centro Ricerche Cliniche di Verona s.r.l.
Verona, 37134, Italy
-
Chiang Mai University
Chiang Mai, 50200, Thailand
-
Clinica Universidad de Navarra
Pamplona, 31008, Spain
-
Clinical hospital center Bezanijska Kosa
Belgrade, 11071, Serbia
-
Clínica Universidad de Navarra
Madrid, 28027, Spain
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
E-DA hospital
Kaohsiung City, Yanchao District, 82445, Taiwan
-
Fondazione IRCCS Policlinico San Matteo
Pavia, 27100, Italy
-
Highlands Oncology Group
Springdale, Arkansas, 72762, United States
-
Hospital Universitario Fundación Jiménez Díaz
Madrid, 28040, Spain
-
Hospital Universitario Miguel Servet
Zaragoza, 50009, Spain
-
Hospital Universitario Quirónsalud
Pozuelo de Alarcón, 28223, Spain
-
Hospital Universitario Virgen del Rocío
Seville, 41013, Spain
-
ICANS
Strasbourg, 67200, France
-
ICO
Angers, 49055, France
-
ICO Hospitalet
Barcelona, 08908, Spain
-
Institute for pulmonary diseases Sremska Kamenica
Kamenitz, 21204, Serbia
-
Instytut MSF Sp zoo
Lodz, 90-302, Poland
-
Istituto Europeo Oncologico
Milan, 20141, Italy
-
Istituto Nazionale Tumori Fondazione G. Pascale
Naples, 80131, Italy
-
Khon Kaen University
Khon Kaen, 40002, Thailand
-
Klinika onkologie a radioterapie, Fakultni Nemocnice Hradec Kralove
Hradec Králové, 50005, Czechia
-
Korea University Hospital
Seoul, 02708, South Korea
-
MD Anderson Cancer Center
Madrid, 28033, Spain
-
MSB General Hospital
Belgrade, 11000, Serbia
-
MSK Cancer Center
New York, New York, 10021, United States
-
Med - Polonia Sp. z o. o.
Poznan, 60-693, Poland
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
NEXT Oncology IOB Hospital Quirónsalud
Barcelona, 08023, Spain
-
NH Hospital a.s.
Hořovice, 268 31, Czechia
-
Narodowy Instytut Onkologii
Warsaw, 02-781, Poland
-
National Cancer centre Singapore
Singapore, 168583, Singapore
-
National Cheng Kung University Hospital
Tainan, 70457, Taiwan
-
National Taiwan University Hospital
Taipei, 10048, Taiwan
-
Next Oncology
San Antonio, Texas, 78229, United States
-
Next Oncology Virginia
Fairfax, Virginia, 22031, United States
-
Onkologicka klinika, Fakultni Nemocnice Olomouc
Olomouc, 77900, Czechia
-
Peninsula & South Eastern Haematology and Oncology Group
Frankston, Victoria, 3199, Australia
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14203, United States
-
S.C. Oncologia Falck, Dipartimento Ematologia ed Oncologia Niguarda Cancer Center
Milan, 20162, Italy
-
START
San Antonio, Texas, 78229, United States
-
Sarawak General Hospital
Kuching, 93586, Malaysia
-
Seoul National University Hospital
Seoul, 3080, South Korea
-
Severance Hospital
Seoul, 3722, South Korea
-
Siriraj Hospital
Bangkok Noi, 10700, Thailand
-
South West Health Care
Warrnambool, Victoria, 3280, Australia
-
Southside Cancer Care Centre
Sydney, New South Wales, 2228, Australia
-
Taipei Tzu Chi Hospital
New Taipei City, 231, Taiwan
-
Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
UC Davis Cancer Center
Sacramento, California, 95817, United States
-
UC Irvine Cancer Center
Orange, California, 92868, United States
-
UCSF
San Francisco, California, 94158, United States
-
University Malaya Medical Centre
Kuala Lumpur, 59100, Malaysia
-
University of Miami School of Medicine Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
Conditions
Explore the condition pages connected to this study.